Back to top

Guggenheim Keeps Their Buy Rating on Sionna Therapeutics, Inc. (SION)

Guggenheim analyst Yatin Suneja reiterated a Buy rating on Sionna Therapeutics, Inc. on July 24 and set a price target of $50.00. The company’s sha...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE: